Rhumbline Advisers Pyxis Oncology, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 68,156 shares of PYXS stock, worth $65,429. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,156
Previous 67,851
0.45%
Holding current value
$65,429
Previous $105,000
31.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PYXS
# of Institutions
100Shares Held
24.3MCall Options Held
993KPut Options Held
42.6K-
Laurion Capital Management LP New York, NY3.63MShares$3.48 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$2.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$2.67 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$2.34 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.04 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $33.7M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...